Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»US News

    Eli Lilly (LLY) earnings Q3 2025

    AdminBy AdminOctober 30, 2025 US News
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    Eli Lilly (LLY) earnings Q3 2025

    Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025.

    Antranik Tavitian | Reuters

    Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.

    Shares of the company rose 5% in premarket trading Thursday.

    The pharmaceutical giant now expects its fiscal 2025 revenue to come in between $63 billion and $63.5 billion, up from a previous guidance of $60 to $62 billion. Eli Lilly also expects full-year adjusted profit to come in between $23 and $23.70 per share, up from its previous outlook of $21.75 to $23 a share.

    Eli Lilly said the guidance reflects President Donald Trump‘s existing tariffs as of Thursday, but does not include his threatened levies on pharmaceuticals imported into the U.S.

    Mounjaro raked in $6.52 billion in revenue for the quarter, up 109% from the same period a year ago. That blew past the $5.51 billion that analysts were expecting, according to StreetAccount. 

    Zepbound, which entered the market roughly two years ago, posted $3.57 billion in revenue for the third quarter. That’s up 184% from the year-earlier period and slightly ahead of the $3.5 billion that Wall Street was expecting, according to StreetAccount estimates.

    Here’s what Eli Lilly reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

    • Earnings per share: $7.02 adjusted vs. $5.69 expected
    • Revenue: $17.60 billion vs. $16.01 billion expected

    The results come as Eli Lilly works to maintain its edge over chief rival Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.

    The company posted third-quarter revenue of $17.60 billion, up 54% from the same period a year ago. 

    Sales in the U.S. jumped 45% to $11.30 billion. Eli Lilly said that was driven by a 60% increase in volume — or the number of prescriptions or units sold — for its products, primarily for Mounjaro and Zepbound. That was partially offset by lower realized prices of the drugs, the company said.

    The pharmaceutical giant booked net income of $5.58 billion, or $6.21 per share, for the third quarter. That compares with net income of $970.3 million, or $1.07 per share, a year earlier. 

    Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $7.02 per share for the second quarter.

    The results underscore Eli Lilly’s strong advantage in the booming GLP-1 drug market.

    The company has gained the majority market share over the last year, thanks to the strong profile of its weight loss and diabetes injections and a boost from its direct-to-consumer sales, among other efforts. Eli Lilly took another stride to boost access to Zepbound on Wednesday, partnering with Walmart to offer in-store pickup of discounted vials of the drug for cash-paying patients.

    The company is now betting on its closely-watched experimental obesity pill, orforglipron, to solidify its dominance in the space, especially as Novo Nordisk and other drugmakers race to bring their own pills or next-generation injections to the market. 

    On Thursday, Novo Nordisk launched a rival bid for U.S. obesity biotech company Metsera, hijacking an offer from Pfizer as it races to catch up to Eli Lilly.

    This story is developing. Please check back for updates.

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Musk regrets nearly $500 million midterm elections spending, says hes not MAGA

    November 19, 2026

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    November 18, 2026

    Federal Reserve's Cook refuses to participate in White House hearing

    November 17, 2026

    The advice Biden got from Mitt Romney, and other takeaways from his memoir

    November 17, 2026

    Lindsay Clancy gets new trial date

    November 16, 2026

    Apple launches an AI health tool as part of a research study

    November 16, 2026
    Popular Posts

    Voyager 1 at one light-day: Historian revisits Golden Record's forgotten details

    DWTS Fans Discover Sneaky Loophole To Rig Votes For Favorite

    James Blunt legally changes name to Ryan Air after scoring Number One album

    French Curl Braids Are the Hairstylist-Approved Protective Style Were Loving—8 Ideas to Inspire Your Next Look

    Noah Kahan Address Grammy Snub in the Most Noah Kahan Way: Lets Move on Together

    California DMV boots Waymo robotaxis off state freeways after string of incidents

    Categories
    • Books (2,456)
    • Business (3,449)
    • Events (34)
    • Film (1,061)
    • LifeStyle (2,922)
    • Music (2,795)
    • Politics (2,355)
    • Science (1,951)
    • Technology (1,816)
    • Television (3,627)
    • US News (3,293)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • Rosamund Pike Joins the Cast of ‘Now You See Me 3’Rosamund Pike Joins the Cast of ‘Now You See Me 3’
    • Kamala Harris promises to fight inflationKamala Harris promises to fight inflation
    • Friday could be a wild day of trading on Wall Street. Here’s whyFriday could be a wild day of trading on Wall Street. Here’s why
    • Trump hush money prosecutor open to trial delay of one monthTrump hush money prosecutor open to trial delay of one month
    • Trump ‘flouting the courts’ in Abrego Garcia caseTrump ‘flouting the courts’ in Abrego Garcia case
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.